Sea4Pain

Direct

Contribution to health through research and development of innovative treatments: with the funding, Sea4Us will continue the development of innovative treatments for chronic pain based on marine compounds. Based on research and development processes, the promoter has created a therapeutic drug from molecules found in a marine sponge, with high efficacy and no serious side effects. The promoter focuses on efficient production and development processes that allow for lower material losses and lower production costs, with the aim of keeping costs low and providing a product that is more accessible to patients.

Creation and maintenance of skilled jobs: the implementation phase to be funded by this campaign will result in one person being hired. Sea4Us, which currently has a team of 19 people, contributes to the creation of highly qualified jobs in the Algarve region of Portugal, with 18 highly qualified people, 10 of whom are PhDs.

Indirect

Promoting the quality of life of patients with chronic pain: through treatment with Sea4Pain, patients will be able to access an effective analgesic medication that reduces pain without adverse side effects and without the potential for addiction, representing an important and necessary alternative to the use of opioids. The non-opioid drugs in this solution provide pain relief and contribute to improving patients' quality of life. The commercialization of Sea4Pain will allow Sea4Us to reinvest in its production, developing new drugs for other pressing clinical needs, and delivering treatments that impact people's lives.

Contribution to the maintenance of marine ecosystems and sustainable marine economic activities: the promoter's central purpose is the protection and maintenance of marine resources, carrying out ecosystem monitoring, recording and managing invasive species, and contributing to the repopulation of native species. Sea4Us is a voluntary signatory of the UN Global Compact, a member of the European Animal Research Association and prioritizes transparency and ethics in its processes.

Promoting the economic and scientific development of the Algarve and Portugal: Sea4Us has its laboratory in Sagres, in the Algarve, where biotechnology activities are carried out, mobilizing a network of dozens of active partners to implement projects and disseminate knowledge in this region of Portugal. In this way, it is possible to raise the potential of the country's marine resources and the development of differentiating activities in the blue economy to an international scale, contributing to local economic development. In addition, through partnerships with universities, it contributes to the advancement of scientific knowledge, having collaborated on seven master's theses already completed at the company, two doctoral theses completed and another five in progress.

Sea4Us - Biotecnologia e Recursos Marinhos, S.A., fundada en 2013, es una empresa biotecnológica portuguesa especializada en el descubrimiento y desarrollo de fármacos innovadores derivados de compuestos marinos para responder a necesidades clínicas sin tratamiento adecuado, como el dolor crónico o inducido por la quimioterapia, la artrosis, la vejiga hiperactiva y las enfermedades infecciosas.

Sea4Us fue creada originalmente por 7 cofundadores inspirados por la enorme biodiversidad marina del Océano Atlántico en Sagres, al sur de Portugal, y fue aquí donde nació la sede y estación marina de Sea4Us.

Sagres sigue siendo el lugar principal para la recogida de muestras marinas y el descubrimiento de nuevos compuestos bioactivos, mientras que el desarrollo preclínico se lleva a cabo en Lisboa, en el Laboratorio de Fisiología.

Spin-off de la Facultad de Medicina NOVA (Universidade Nova de Lisboa), Sea4Us combina su experiencia en biología marina y electrofisiología para identificar compuestos diferenciadores, desarrollarlos en nuevos fármacos y llevar a cabo su validación preclínica y de seguridad.

La promotora aspira a ser una empresa biotecnológica de referencia mundial en la investigación y el desarrollo de productos farmacéuticos. Sea4Us también pretende sistematizar y ampliar las actividades y servicios de la empresa que promuevan el intercambio y la valorización de los conocimientos biotecnológicos adquiridos, contribuyendo a la sostenibilidad científica y económica de la empresa y al desarrollo de la región del Algarve.

Sea4Us y Sea4Pain han sido reconocidos por la Unión Europea a través del «EIC-Accelerator», un Programa del Consejo Europeo de Innovación (CEI). Este Programa distingue el desarrollo de este nuevo medicamento y su impacto en la sociedad y en la calidad de vida de los pacientes, y apoya su desarrollo hasta los primeros ensayos clínicos en humanos.